Eliciting tyrosine-sulfated neutralizing antibodies recognizing the Env apex
Eliciting tyrosine-sulfated neutralizing antibodies recognizing the Env apex
批准号:
10013483
负责人:
Michael R. Farzan
金额:
$23.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-03-06 至 2022-02-28
关键词:
AbbreviationsAffinityAntibodiesAntibody DiversityAntigen TargetingAntigensB-LymphocytesBindingBinding SitesCharacteristicsDataEngineeringEpitopesFoundationsGenesGlycoproteinsGoalsHIVHIV-1HIV-1 vaccineHemocyaninHumanImmune SeraImmunizationImmunizeImmunoglobulin Somatic HypermutationIndividualKeyhole Limpet HemocyaninKnowledgeLightModelingMutationPolysaccharidesPopulationPropertyProtein FamilyRattusReceptors, Antigen, B-CellSideSulfateTestingTransferaseVaccinesWistar RatsWorkbasecomplementarity-determining region 3crosslinkdesigndisulfide bondinterestnanoparticleneutralizing antibodynonhuman primatenovel strategiespreventprotein-tyrosine sulfotransferasescaffoldsuccesstransmission processtyrosine O-sulfate
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
An effective HIV-1 remains an important but elusive goal. One promising approach to such a vaccine
uses sequential immunization to guide B-cell receptor (BCR) maturation. To do so, one first amplifies
immature unmutated precursors of a particular class of broadly neutralizing antibodies (bNAbs). These
precursor BCR are then shepherded to recognize HIV-1 envelope glycoprotein (Env) using increasingly
native Env antigens. Sequential immunization strategies for both VRC01- and V3-glycan-classes of
bNAbs are being developed. Here we establish the foundations for using the same general strategy to
elicit V2-glycan/apex antibodies. Apex bNAbs have properties that both complicate such an approach
but ultimately make success more likely. Specifically these bNAbs bind Env largely through their long,
acidic and tyrosine-sulfated heavy-chain CDR3 region. Thus there is less need for extensive somatic
hypermutaion characteristic of V3-glycan and VRC01-class bNAbs. However, apart from their long
sulfated CDR3 regions, apex bNAbs have few distinguishing features. Here we show that we can elicit
antibodies in rats with long tyrosine-sulfated CDR3 regions using anti-sulfotyrosine antibodies as
antigens. We propose to optimize this approach and use it in concert with oligomeric forms of Env trimers
to elicit anti-apex antibodies. These studies will develop a potentially easier approach to generating
broad and potent anti-HIV-1 antisera.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
eCD4-mediated control of SIV infection in the brain
-
批准号:10698442
-
项目类别:
-
资助金额:$91.41万
-
财政年份:2023
-
负责人:Michael R. Farzan
-
依托单位:
Safe, CRISPR/Cas-free B cell editing for therapeutic applications
-
批准号:10725412
-
项目类别:
-
资助金额:$22.13万
-
财政年份:2023
-
负责人:Michael R. Farzan
-
依托单位:
Improving mRNA vaccines with extracellular vesicle-associated immunogens
-
批准号:10573644
-
项目类别:
-
资助金额:$8.28万
-
财政年份:2022
-
负责人:Michael R. Farzan
-
依托单位:
Targeting druggable coronavirus proteins
-
批准号:10514326
-
项目类别:
-
资助金额:$578.68万
-
财政年份:2022
-
负责人:Michael R. Farzan
-
依托单位:
Improving mRNA vaccines with extracellular vesicle-associated immunogens
-
批准号:10850617
-
项目类别:
-
资助金额:$18.96万
-
财政年份:2022
-
负责人:Michael R. Farzan
-
依托单位:
Engineering CAR-B cells for an HIV-1 functional cure
-
批准号:10514882
-
项目类别:
-
资助金额:$69.5万
-
财政年份:2022
-
负责人:Michael R. Farzan
-
依托单位:
Engineering CAR-B cells for an HIV-1 functional cure
-
批准号:10844837
-
项目类别:
-
资助金额:$74.11万
-
财政年份:2022
-
负责人:Michael R. Farzan
-
依托单位:
Therapeutic Use of an Enhanced Form of CD4-Ig
-
批准号:9970576
-
项目类别:
-
资助金额:$92.43万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Therapeutic use of an enhanced form of CD4-Ig
-
批准号:10851165
-
项目类别:
-
资助金额:$20.01万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Core B: Non-human primate core
-
批准号:10625274
-
项目类别:
-
资助金额:$55.2万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Project 4: A permanent off-switch for AAV
-
批准号:10625294
-
项目类别:
-
资助金额:$35.43万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Core A: Administrative Core
-
批准号:10381474
-
项目类别:
-
资助金额:$56.54万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Therapeutic Use of an Enhanced Form of CD4-Ig
-
批准号:10591713
-
项目类别:
-
资助金额:$27.53万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Therapeutic Use of an Enhanced Form of CD4-Ig
-
批准号:10534766
-
项目类别:
-
资助金额:$72.17万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
An AAV-mediated functional cure and its impact on the reservoir
-
批准号:10625272
-
项目类别:
-
资助金额:$260.96万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Core A: Administrative Core
-
批准号:10625273
-
项目类别:
-
资助金额:$4.7万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Core B: Non-human primate core
-
批准号:10381475
-
项目类别:
-
资助金额:$60.27万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
An AAV-mediated functional cure and its impact on the reservoir
-
批准号:10381472
-
项目类别:
-
资助金额:$313.69万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
Project 4: A permanent off-switch for AAV
-
批准号:10381480
-
项目类别:
-
资助金额:$67.16万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
An AAV-mediated functional cure and its impact on the reservoir
-
批准号:9891590
-
项目类别:
-
资助金额:$293.89万
-
财政年份:2020
-
负责人:Michael R. Farzan
-
依托单位:
海外基金